discontinuing glp-1 Most adults with overweight or obesity discontinue therapy within 2 years What really happens when patients

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has garnered attention for its dual benefits of blood sugar control and weight loss

Regional Analysis for Glucagon-like Peptide 1 (GLP-1) Analogues Market: North America (U.S., Canada, Mexico) Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe) Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific) South America (Colombia, Brazil, Argentina, Rest of South America) Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa) **The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted** This Report Covers: Go-to-market Strategy

doi: 10.1053/j.gastro.2007.08.061

Key Takeaways Nausea is one of the most common side effects of GLP-1 medications and is usually most noticeable when starting treatment or increasing your dose